CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today publication of a study by Sirtris and Harvard University scientists in the journal Cell that reveals a new mechanism to slow aging. This study shows for the first time that activation of SIRT3 and SIRT4, members of the sirtuin family of enzymes, protects against cell damage. These important new findings further validate sirtuins as important targets for treating diseases of aging.
